Status:
RECRUITING
The Role of Melatonin as an Adjuvant Therapy in Childhood Pneumonia
Lead Sponsor:
Mian Muhammad Hassan Ahmed
Conditions:
Pneumonia Childhood
Eligibility:
All Genders
1-12 years
Phase:
PHASE1
PHASE2
Brief Summary
The goal of this study is to compare the mean length of hospital stay between children with pneumonia receiving melatonin as an adjuvant therapy and those receiving standard of care alone. The hypoth...
Detailed Description
OPERATIONAL DEFINITION: Pneumonia: defined as patient having fast breathing; * 50 breaths/min in a child aged 2-11 months * 40 breaths/min in a child aged 1-5 years Chest in-drawing Severe Pneumoni...
Eligibility Criteria
Inclusion
- 1 month to 12 years
- Both genders
- Patient diagnosed as having pneumonia or severe pneumonia according to WHO definition
Exclusion
- Hospitalized within 14 days prior to the study
- Known TB exposure
- Active varicella or herpes simplex infection
- Allergy to the study medication
- Currently taking melatonin
- Any non pneumonia acute medical illness which requires antibiotic treatment as per local standard of care
- Galactose intolerance, the lapp-lactase deficiency or glucose-galactose malabsorption
- Significant co-morbid disease: lung, cardiac, immune, liver, endocrine, neurological or psychiatric
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06949904
Start Date
May 1 2025
End Date
January 1 2026
Last Update
April 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pakistan Institute of Medical Sciences
Islamabad, Islamabad, Pakistan, 44000